Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: twentyfirstcenturyfox who wrote (8029)	11/16/2001 11:20:02 AM
From: E. T.	Read Replies (1) \| Respond to of 14101

That question would best be directed toward Wolf, Cal, john, Joe or Ron. eom

To: twentyfirstcenturyfox who wrote (8029)	11/16/2001 12:44:39 PM
From: Montana Wildhack	Respond to of 14101

Fox, that it is essentially the DMX active transdermal ingredient which is the unknown factor I believe that is correct. The delay in Canada was caused partly by the small number of valid patients from the first phase III. The second was comprehensive and had strong results. The "delays" are also I believe caused by the smallness of Dimethaid and its inability to pressure the way a Merck can. The large pharma's always have various drugs in various stages of approval and their relationships with the approving bodies are better developed - which with people involved in the decision making is important. The second phase III was also given to the FDA which has an open process similar to the UK - but completely different from Canada which has a closed process (you answer questions but thats it). Europe can best be understood by comparing our results with the approval results of both Celebrex and Vioxx - who had similar experiences in Europe. There is still some concern about using DSMO as the active transfer agent. This is because of its history as a paint thinner and its garlic presence. Those issues are not valid in this compound form in that the dilution does not present a danger in comparison to oral NSAID's side effects. Of the 20 or so people I've spoken to using Pennsaid not one has detected a garlic taste. The last point I believe is the undue influence that the drug majors have in the whole process. As in most 'turf' issues with humans - I have no doubt there is influence being exerted by them to slow any and every form of competition down. ..... Currently there is a lid on the stock caused by the 40,000 offer sitting just behind the action with no real intent to transact. The price range is caused by the european results, the 95,000 in revenue, and the absence of announced steps forward in further approvals or partnerships. If Joe is right (and I suspect he is) this may be an intent not to let the price rebound from the last placement and keep proceeds down. I suspect a shakeup is underway beyond the normal experiences we have seen and the intent is to break the long term support line and break the support for this stock. Having said that, if we were seeing a decision to exit by informed big players - we would weeks ago have been in the $2 range on big volume. These are games of influence while DMX is down with some new purpose. We'll see what happens when they succeed in breaking the $3.50 on the downside. Not a great period for DMX long term supporters and no doubt a strain for the people working to make DMX succeed. I've heard every imaginable version including that the UK is just a hoax. Its not suprising what comes out of peoples mouths when they're frustrated and investments aren't working out. I'm refering to this as DMX's "dark period". Wolf